Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

YOU WONT BELIEVE: Benzinga s top ratings upgrades downgrades for march 1 2022 - You Need To See This

Upgrades

Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71, compared to year-ago quarter EPS of $0.52. The stock has a 52-week-high of $50.88 and a 52-week-low of $18.07. At the end of the last trading period, Revolution Medicines closed at $18.92.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.